



truscreen
a world without
cervical cancer

NZX/ASX Announcement

2 June 2025

TruScreen Raises NZ\$2.3 Million in Share Placement

Truscreen Group Limited (NZX/ASX:TRU) is pleased to advise that further to the announcement of 29 May 2025 “Truscreen announces the opening of a NZ\$3.0 capital raise”, the Company has received firm commitments from both new and existing investors for an initial Placement of 107,034,091 shares at NZ\$0.022/A\$0.02 each to raise NZ\$2,354,750, before costs.

Of these shares approximately 80.9 million will be issued under the Company’s existing 15% placement capacity, with the balance being subject to shareholder approval at a meeting to be held on 11 July 2025.

In addition, the Company will issue one free attaching option, for each new share issued, with an exercise price NZ\$0.022 and an expiry date of one year from the date of issue, subject to shareholder approval on 11 July 2025.

The share purchase plan offer (see SPP Offer Booklet lodged with NZX/ASX on 29 May 2025), will open on 3 June 2025 providing eligible shareholders on the record date of 28 May 2025, the opportunity to purchase up to NZ\$50,000 (A\$45,000) worth of new Shares per eligible shareholder at an issue price of the lower of (i) NZ\$0.022 / A\$0.02 per SPP Share; and (ii) a price equal to a 2.5% discount to the VWAP of TruScreen shares traded on the NZX and ASX during the 5 trading days up to, and including, the end of the SPP offer period, being 23 June 2025.

Under the SPP the Company is limited under the listing rules to raise up to an aggregate of NZ\$1,220,796 (A\$1,119,996), however the Board may accept oversubscriptions which will be subject to Shareholder approval. Each new share issued under the SPP will also be entitled to one free attaching option as outlined above, subject to shareholder approval.

Tony Ho Chairman commented, “*we are pleased with the strong support that we have received for this placement and welcome new institutional shareholders from Singapore and Hong Kong. This acknowledges the achievements TruScreen has made in the past year, and with these initiatives in place, the significant opportunities we have in the year ahead*”.

SPP application forms will be dispatched on 3 June 2025. In the event shareholders do not receive application forms please contact the share registry MUFG Corporate Markets: applications.nz@cm.mpms.mufg.com (Please use “TruScreen SPP”) as the subject of the email, or Telephone +64 9 375 5998 or contact the Company Secretary, contact details below.

This announcement has been approved by the Board.

Ends

Guy Robertson
Company Secretary
Tel: +61 407 983 270
Email: guyrobertson@truscreen.com

For more information, visit www.truscreen.com or contact:

Mr Martin Dillon
Chief Executive Officer
martindillon@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's cervical screening technology enables cervical screening, negating sampling and processing of biological tissues, failed samples, missed follow-up, discomfort, and the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen Ultra[®], is typically registered as a primary screening device for cervical cancer screening.

The device is CE Marked/EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Israel and the Philippines, among others and has distributors in over 20 countries. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

TruScreen technology has been recognised in CSCCP's (Chinese Society for Colposcopy and Cervical Pathology) China Cervical Cancer Screening Management Guideline.

TruScreen has been recognised in a China Blue Paper "Cervical Cancer Three Stage Standardized Prevent and Treatment" published on 28 April 2023.

In Dec 2023 TruScreen technology was added to the Vietnam Ministry of Health approved National Technical List, for use in Vietnam's public and private healthcare sectors and in 2024 was added to the Russian guidelines for the screening of cervical cancer.

In financial year 2025 alone, approximately 150,000¹ examinations were performed with the TruScreen device. To date, over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer"[®].

To learn more, please visit: www.truscreen.com/.

¹Based on Single Use Sensor sales.